Latest Articles

Publication Date
Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent dMMR Endometrial Cancer - epi-phare

Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent dMMR Endometrial Cancer epi-phare

Published: March 9, 2026, 10:32 a.m.
Endometrial cancer: AIFA approves immunotherapy with chemotherapy for all patients. - lamilano.it

Endometrial cancer: AIFA approves immunotherapy with chemotherapy for all patients. lamilano.it

Published: Feb. 23, 2026, 1:30 p.m.
Fertility preservation in women with endometriosis: How, when, and for whom?

Fertility preservation options, including cryopreservation of oocytes, embryos, and ovarian tissue, were initially focused on women undergoing gonadotoxic chemotherapy for oncologic treatment. The indications have expanded to include nonmalignant conditions …

Published: Feb. 20, 2026, midnight
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - BioSpace

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer BioSpace

Published: Feb. 4, 2026, 4:47 a.m.
Gsk - Quebec To Reimburse Jemperli Plus Chemotherapy Via Ramq For Primary Advanced/First Recurrent Endometrial Cancer - TradingView

Gsk - Quebec To Reimburse Jemperli Plus Chemotherapy Via Ramq For Primary Advanced/First Recurrent Endometrial Cancer TradingView

Published: Feb. 3, 2026, 1:11 p.m.
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - Newswire Canada

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer Newswire …

Published: Feb. 3, 2026, 1 p.m.
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - Yahoo Finance Singapore

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer Yahoo …

Published: Feb. 3, 2026, 1 p.m.
Emerging Trends and Treatment Strategies in Ovarian Cancer: A Comprehensive Review.

Ovarian cancer (OC) is the eighth leading cause of cancer deaths in women globally, mainly originating from epithelial cells. It is further divided into type-I and type-II based on histology, …

Published: Feb. 3, 2026, midnight
HIF2A as a prognostic and clinical therapeutic target in ovarian clear cell carcinoma.

Ovarian clear cell carcinoma (CCC) is an aggressive subtype of ovarian cancer that is resistant to conventional chemotherapy, resulting in poor prognosis. CCC develops from endometriosis, which exposes tumor cells …

Published: Jan. 27, 2026, midnight
Management of Suspected Stage IVA Endometrial Cancer With Rectosigmoid Involvement Using Neoadjuvant Chemotherapy and Interval Surgery - Cureus

Management of Suspected Stage IVA Endometrial Cancer With Rectosigmoid Involvement Using Neoadjuvant Chemotherapy and Interval Surgery Cureus

Published: Jan. 21, 2026, 1:51 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!